Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with two separate inj...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Phenobarbital May Top'First-Line' Approach to Alcohol Withdrawal Phenobarbital May Top'First-Line' Approach to Alcohol Withdrawal
The barbiturate/anticonvulsant phenobarbital may be a better alternative to hypnotics, specifically lorazepam, the current first-line approach, for alcohol withdrawal syndrome, new research suggests.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 11, 2019 Category: Internal Medicine Tags: Psychiatry News Source Type: news
hyoscyamine, atropine, scopolamine and phenobarbital (Donnatal)
Title: hyoscyamine, atropine, scopolamine and phenobarbital (Donnatal)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/12/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 12, 2019 Category: Nutrition Source Type: news
C.O. Truxton, Inc. Issues Voluntary Nationwide Recall of Amitriptyline HCL Tablets, USP 50mg and Phenobarbital Tablets, USP 15mg, 30mg, 60mg, 100mg Due to Potential Label Mix-Up
Bellmawr, New Jersey, C.O. Truxton, Inc. is expanding their 04/21/2017 voluntary recall, as a precaution to include the following C.O. Truxton, Inc. products, registered NDC numbers and corresponding lot numbers, to the consumer/user level. C.O. Truxton has not received any complaints for the products listed below. however, due to the initial recall resulting from a label mix-up error, out of an abundance of caution, we are recalling all products that were repackaged into a Truxton Incorporated label. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
C.O. Truxton, Inc. Issues Voluntary Nationwide Recall of Phenobarbital 15 mg Tablets, USP due to Labeling Error on Declared Strength
Bellmawr, New Jersey, C.O. Truxton, Inc. is voluntarily recalling lot 70952A of Phenobarbital Tablets, USP, 15 mg, to the consumer/user level. The manufacturer received a confirmed customer complaint that a bottle labeled as phenobarbital 15 mg was found to contain phenobarbital 30 mg tablets. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 24, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Class 4 medicines defect information: phenobarbital sodium 30mg/ml injection
Martindale Pharma has informed the MHRA that the EAN bar code for certain batches is incorrect. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 8, 2019 Category: Drugs & Pharmacology Source Type: news
Phenobarbital (Phenobarbital) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 5, 2019 Category: Drugs & Pharmacology Source Type: news
Toxicology Rounds: Is Phenobarbital for Alcohol Withdrawal Ready for the Big Time?
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - April 1, 2018 Category: Emergency Medicine Tags: Toxicology Rounds Source Type: news
Levetiracetam Bests Phenobarbital in Infantile Epilepsy (CME/CE)
(MedPage Today) -- Study addresses mismatch between clinical practice and regulatory approval (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 13, 2018 Category: Neurology Source Type: news
